HRT formulations

Details for Australian Patent Application No. 2004275469 (hide)

Owner Novo Nordisk Femcare AG

Inventors Edwards, William Martin; Jensen, Moller Bente; Shalmi, Michael

Agent Shelston IP

Pub. Number AU-B-2004275469

PCT Pub. Number WO2005/030175

Priority 60/536,121 13.01.04 US; PA 2003 01408 29.09.03 DK; 60/509,962 09.10.03 US; PA 2003 01828 10.12.03 DK

Filing date 21 September 2004

Wipo publication date 7 April 2005

Acceptance publication date 15 July 2010

International Classifications

A61K 9/20 (2006.01) Medicinal preparations characterised by special physical form - Pills, lozenges or tablets

A61K 31/565 (2006.01) - not substituted in position 17 beta by a carbon atom, e.g. oestrane, oestradiol

A61K 31/567 (2006.01) - substituted in position 17 alpha, e.g. mestranol, norethandrolone

Event Publications

6 April 2006 PCT application entered the National Phase

  PCT publication WO2005/030175 Priority application(s): WO2005/030175

15 July 2010 Application Accepted

  Published as AU-B-2004275469

11 November 2010 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2004275470-Improved stability of progestogen formulations

2004275451-Methods for preparing oil bodies comprising active ingredients